Streetbeat News

Price Targets

YOU

Telsey Advisory Group has reiterated its 'Outperform' rating on Clear Secure (NYSE:YOU) and maintained its price target of $34.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:47 am

TSCO

Telsey Advisory Group analyst Joseph Feldman has reiterated an 'Outperform' rating on Tractor Supply (NASDAQ:TSCO) and maintained a price target of $265.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:46 am

FIGS

Telsey Advisory Group has reiterated its 'Outperform' rating on FIGS (NYSE:FIGS) and maintained its price target of $11.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:45 am

COUR

Telsey Advisory Group analyst Sarang Vora has reiterated an 'Outperform' rating on Coursera (NYSE:COUR) and maintained a $20 price target.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:44 am

LUV

Raymond James analyst Savanthi Syth has downgraded Southwest Airlines from Strong Buy to Outperform and lowered the price target from $47 to $40.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:38 am

VLY

Piper Sandler analyst Matthew Breese has downgraded Valley National (NASDAQ:VLY) from Overweight to Neutral, while raising the price target from $10 to $11.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:37 am

PRFT

JP Morgan analyst Puneet Jain has downgraded Perficient (NASDAQ:PRFT) from Overweight to Neutral and lowered the price target from $84 to $70.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:35 am

FIXX

Baird analyst Madhu Kumar has downgraded Homology Medicines (NASDAQ:FIXX) from Outperform to Neutral and lowered the price target from $9 to $1.5.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:33 am

TSVT

Morgan Stanley analyst Matthew Harrison has downgraded 2seventy bio (NASDAQ:TSVT) from Overweight to Equal-Weight and lowered the price target from $25 to $13.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:31 am

MRSN

Baird analyst Colleen Kusy has downgraded Mersana Therapeutics (NASDAQ:MRSN) from Outperform to Neutral and lowered the price target from $7 to $1.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:30 am